Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alexion buys Achillion for $930mm in cash

Executive Summary

Alexion Pharmaceuticals Inc. is acquiring fellow publicly traded rare disease firm Achillion Pharmaceuticals Inc. for $930mm in cash ($6.30 per share; a 71% premium). Alexion gets Achillion’s cash which was about $230mm as of the end of September. Alexion will fund the transaction through its cash on hand.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Full Acquisition
    • Payment Includes Cash
    • Includes Earnout
    • Intra-Biotech Deal

Related Companies